Unlock Advanced Preclinical Insights with the SRG Rat®

The SRG Rat is already revolutionizing cancer research. What can it do for your project?

Hera BioLabs’ proprietary, cutting-edge model, the SRG RAT® is immunodeficient and highly permissive to human xenografts. Developed on the Sprague-Dawley background, the SRG Rat is a Rag2/IL2Rγ double knockout that lacks mature B cells, T cells, and circulating NK cells. Cell lines that are often challenging in mice, with variable take rates and growth kinetics, grow consistently better in the SRG Rat, allowing you to achieve more accurate and efficient results in your studies.

 

The SRG Rat has Several KEY Advantages Over Traditional Rodent Models

Beyond the SRG Rat, the Hera team offers other standard and custom rodent xenograft programs such as syngeneic rat and mouse studies, studies in nude and wild-type rats, and immunodeficient and wild-type mice.

What You’ll Learn:

  • The unique benefits of the SRG Rat model for human xenograft studies, including serial tumor biopsies and PK blood sampling.

  • A detailed overview of validated applications, with orthotopic glioblastomas, difficult-to-engraft tumor types, and our suite of validated colorectal and prostate models.
  • Other mouse and rat models for traditional oncology and immuno-oncology.
  • How working with our experienced team can enhance your project outcomes.

“The tumor uptake rate was 80-100%, which is a huge advantage because what we could achieve as statistical significance with 8-12 mice, can be achieved with 5-6 SRG Rats®.”

Ramesh Narayanan, Ph.D. Associate Professor of Medicine & Hematology, UTHSC